The ALEC Study is funded by the European Union's Horizon 2020 Research and Innovation programme under grant agreement No. 633212.
Horizon 2020 is the EU's biggest ever Research and Innovation programme, with nearly €80 billion of funding available over 7 years (2014 to 2020) – in addition to the private investment that this money will attract. It promises more breakthroughs, discoveries and world-firsts by taking great ideas from the lab to the market.
Two of the collaborating cohorts in the ALEC Study are based in countries outside of the European Union. The SAPALDIA cohort is based in Switzerland and the TAHS cohort is based in Australia. Further funding for the ALEC Study has been provided by The State Secretariat for Education, Research and Innovation (SERI), Switzerland, and the Australian National Health and Medical Research Council (NHMRC).